Edition:
United States

ADMA Biologics Inc (ADMA.A)

ADMA.A on American Stock Exchange

3.02USD
18 Aug 2017
Change (% chg)

$-0.05 (-1.63%)
Prev Close
$3.07
Open
--
Day's High
$3.02
Day's Low
$3.02
Volume
0
Avg. Vol
--
52-wk High
$3.68
52-wk Low
$2.90

ADMA.A

Chart for ADMA.A

About

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments... (more)

Overall

Beta: 2.18
Market Cap(Mil.): $78.41
Shares Outstanding(Mil.): 25.79
Dividend: --
Yield (%): --

Financials

  ADMA.A Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -1.75 -- --
ROI: -51.15 2.83 14.89
ROE: -154.84 5.09 16.13

BRIEF-ADMA Biologics Q2 loss per share $0.55

* ADMA Biologics provides corporate update and reports second quarter 2017 financial results

Aug 11 2017

BRIEF-U.S. Patent and Trademark Office issues immunotehrapy patent to Adma Biologics

* Adma Biologics - U.S. Patent and trademark office has issued to co U.S. Patent no. 9,714,283 which encompasses methods of providing immunotherapy to patients

Jul 31 2017

BRIEF-ADMA Biologics provides corporate timeline and activities update

* ADMA Biologics provides corporate timeline and activities update to stockholders

Jun 27 2017

BRIEF-ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock

* ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock by the selling shareholders Source text: (http://bit.ly/2twQ4Bo) Further company coverage:

Jun 16 2017

BRIEF-Biotest ‍sells US therapy business to Adma Biologics, Inc.​

* ‍RECEIVES ALSO DISTRIBUTION RIGHTS OF SPECIFIED CURRENT PRODUCT AND A RIGHT OF FIRST OFFER FOR DISTRIBUTION OF FUTURE PRODUCTS OF ADMA FOR EUROPE, NEAR AND MIDDLE EAST AND SELECTED ASIAN COUNTRIES​

Jun 07 2017

BRIEF-ADMA Biologics Q1 loss per share $0.51

* ADMA Biologics provides corporate update and reports first quarter 2017 financial results

May 12 2017

Competitors

  Price Chg
Baxter International Inc (BAX.N) $60.87 +0.05
Biotest AG (BIOG.DE) €27.43 -0.47
Biotest AG (BIOG_p.DE) €22.81 -0.10

Earnings vs. Estimates